Join us to learn how to accelerate spatial biology discoveries by 70% with optimized, ready-to-go panels using SignalStar™ Multiplex IHC.

Many current spatial biology and multiplex immunohistochemistry technologies involve time-consuming methods for panel optimization, validation, and analysis—which typically take weeks to months, slowing down scientific discovery. With SignalStar Multiplex IHC, researchers can generate results in as little as two days with optimized, ready-to-go panels.

Join us for a webinar led by Dr. Sarah Klein, Associate Director of Multiplex Assay Development at Cell Signaling Technology, to learn about SignalStar Multiplex IHC, an innovative technology that empowers spatial biology research that harnesses the synergy of specific primary antibodies and a network of fluorescent oligonucleotides to efficiently amplify the signal of cellular proteins in formalin-fixed, paraffin-embedded (FFPE) tissue samples.

With SignalStar Multiplex IHC, you gain:

  • Rapid Insights: Generate results in 2 days with optimized, ready-to-go panels
  • Visual Clarity: Detect and visualize up to 8 targets in FFPE tissue
  • Amplified Precision: Amplify the signal of targets with low levels of expression
  • Instant Start: Leverage ready-to-go protocols that are validated and optimized to work out of the box
  • Seamless Integration: Easily employ your existing fluorescent imagers 


Key Topics Include:

  • How SignalStar Multiplex IHC works—an overview of the mechanics and how it unlocks spatial insights
  • How SignalStar Multiplex IHC demonstrates reproducibility and flexibility
  • How to design experiments efficiently with a user-friendly online panel builder—enabling precision planning

Who Should Attend?

  • Researchers using spatial biology technologies, especially multiplex immunohistochemistry
  • Researchers running high-throughput analyses interested in efficient mid-plex immunohistochemistry assays
  • Translational immuno-oncology researchers exploring the spatial context of tumor microenvironments


Associate Director
Multiplex Assays Group
Cell Signaling Technology

Sarah Klein, PhD, is the Associate Director of the Multiplex Assays Group at Cell Signaling Technology (CST). This group was instrumental in the development and validation of SignalStarTM Multiplex IHC. Dr. Klein has been with CST for 7 years, developing antibody-based solutions in the fields of immunology and oncology. She performed her postdoctoral research at Dana Farber Cancer Institute in Boston, MA, and her doctoral research at MD Anderson Cancer Center in Houston, TX, studying the mechanisms of action for immunotherapeutics used in the treatment of cancer, particularly glioblastomas.

Production Partner

Cell Signaling Technology Inc.

Cell Signaling Technology (CST) is a different kind of life sciences company—one founded, owned, and run by active research scientists, with the highest standards of product and service quality, technological innovation, and scientific rigor for over 20 years. We consistently provide fellow scientists around the globe with best-in-class products and services to fuel their quests for discovery.

Additional Content From Cell Signaling Technology Inc.

Additional Content From

Related Content